You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils

Adjuvant Radiotherapy Post-Prostatectomy in T3 or Margin Positive Prostate Cancer

Version: 3 ID: 3-17 May 2014
Type of Content: Guidelines & Advice, Clinical
Document Status: Archived
Authors:
S.C. Morgan, C. Walker-Dilks, L.J. Eapen, E.W. Winquist, J.L. Chin, D.A. Loblaw , Genitourinary Cancer Disease Site Group

Patient Population

Men who have undergone radical prostatectomy for clinically localized prostate cancer and who have been found to have either positive surgical resection margins (R1), tumour extension beyond the prostatic capsule (pT3a), seminal vesicle invasion (pT3b), or more than one of these features.

Intended Guideline Users

Clinicians and healthcare providers involved in the management or referral of men with prostate cancer

Research Question(s)

Does adjuvant radiotherapy (RT) following radical prostatectomy improve clinically important outcomes in patients with pathologic T3 or margin-positive prostate cancer compared with no adjuvant radiotherapy?

The primary outcome of interest is overall survival (OS). Outcomes of secondary interest include prostate cancer-specific survival, metastasisfree survival, biochemical progression-free survival (bPFS), locoregional recurrence-free survival, time to initiation of androgen deprivation therapy (ADT), incidence of acute and late toxicity, and quality of life.

pdf download Full Report (PDF) (823.02 KB)